anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: Catheter-associated urinary tract infections (CAUTIs) account for a large proportion of healthcare-associated infections and have a significant impact on morbidity, length of hospital stay, and mortality. Adherence to the recommended infection prevention practices can effectively reduce the incidence of CAUTIs. This study aimed to assess the characteristics of CAUTIs and the efficacy of prevention programs across hospitals of various sizes.
METHODS: Intervention programs, including training, surveillance, and monitoring, were implemented. Data on the microorganisms responsible for CAUTIs, urinary catheter utilization ratio, rate of CAUTIs per 1,000 device days, and factors associated with the use of indwelling catheters were collected from 2017 to 2019. The incidence of CAUTIs and associated data were compared between university hospitals and small- and medium-sized hospitals.
RESULTS: Thirty-two hospitals participated in the study, including 21 university hospitals and 11 small- and medium-sized hospitals. The microorganisms responsible for CAUTIs and their resistance rates did not differ between the two groups. In the first quarter of 2018, the incidence rate was 2.05 infections/1,000 device-days in university hospitals and 1.44 infections/1,000 device-days in small- and medium-sized hospitals. After implementing interventions, the rate gradually decreased in the first quarter of 2019, with 1.18 infections/1,000 device-days in university hospitals and 0.79 infections/1,000 device-days in small- and medium-sized hospitals. However, by the end of the study, the infection rate increased to 1.74 infections/1,000 device-days in university hospitals and 1.80 infections/1,000 device-days in small- and medium-sized hospitals.
CONCLUSION: We implemented interventions to prevent CAUTIs and evaluated their outcomes. The incidence of these infections decreased in the initial phases of the intervention when adequate support and personnel were present. The rate of these infections may be reduced by implementing active interventions such as consistent monitoring and adherence to guidelines for preventing infections.
Cohort 1: Newly enrolled participants with r/r PTCL who were never exposed to AZD4205. Cohort 2: Participants from other completed AZD4205 study if they are still benefiting from AZD4205.
Participants received a single, intranasal dose of 0.2 millilitre (mL) (approximately 0.1 mL in each nostril) FluMist trivalent influenza virus vaccine live on Day 0 of the study. Each dose of FluMist vaccine contained 10\^7 fluorescent focus units (FFU) of three influenza virus strains namely, A/New Caledonia/20/99 (H1N1), A/Wyoming/03/2003 (H3N2) (A/Fujian/411/2002-like) and B/Jilin/20/2003 (B/Shanghai/361/2002-like).
The present invention relates to multimeric hemoglobin-like proteins wherein two or more tetramers or pseudotetramers are covalently bonded. Between any pair of covalently linked tetramers, the covalent linkage may take the form of a crosslink between two cysteine residues of different polypeptide chain, or of a peptide linker connecting the "carboxy most" residue of a globin-like domain of one tetramer with the "amino most" residue of a similar domain of a second tetramer. Preferably, the multimeric hemoglobin-like protein-containing composition is at least 50% monodisperse, more preferably, at least 95% monodisperse. Although free hemoglobin purified from natural sources may be polymerized by chemical crosslinking to increase halflife via increased molecular weight, and to reduce oncotic pressure, all such preparations are heterogeneous. Monodispersability can be achieved only by laborious purification. The present invention provides means of exerting strict control over the degree of polymerization of hemoglobin tetramers. The ability to strictly control formation of multimers will greatly facilitate purification and characterization of the final product and will reduce the chance of adverse reaction to minor components. It is also believed that a more mono-disperse composition will have greater consistency of clinical effect.
PURPOSE:To provide the titled preparation for the detection of thrombus and useful for the nucleo-medical diagnosis, by contacting blood platelet with a materaminol preparation labeled with radioactive iodine. CONSTITUTION:Collected blood is added with an anticoagulant, and centrifuged to remove erythrocyte and leukocyte from the blood. A proper amount of a metaraminol preparation labeled with radioactive iodine is added to the blood and incubated. The incubated blood is centrifuged again to collect only the blood platelet component labeled with radioactivity, aseptically. The component is mixed with a proper solution allowed usually as a medicine to obtain the blood platelet preparation labeled with radioactive iodine. The preparation may contain further a stabilizing agent to prevent the decomposition with radiation, an isotonic agent such as NaCl, a preservative such as benzyl alcohol, and an acid or base for the control of pH. Dose: as low as possible to minimize the exposure of the patient to radiation, and preferably 0.05-10mCi.
Water movement across the cell membrane is crucial, with red blood cells (RBCs) experiencing the flow of water in both directions at a rate of approximately 100 times their volume per second. This process typically results in no net water flow due to an equal balance of water movement in opposite directions, a phenomenon known as osmosis, driven by water potential or impermeant solute concentration. Understanding osmosis is essential for both physiology and medical practice, yet its complexity may not be effectively conveyed to the students through traditional teaching methods. This study presents a novel approach to observing the osmotic effect on RBCs using a simple, modified blood film technique. Aimed at enhancing educational understanding of cellular behavior in different osmotic environments, this method provides a practical hands-on learning experience. By applying various osmotic solutions to prepared blood films and observing the resultant morphological changes in RBCs under a microscope, this technique allows for direct visualization of osmosis in action.NEW & NOTEWORTHY This study presents an innovative teaching approach for understanding osmosis and its effects on red blood cells. Using a simple, modified blood film technique, students can visually observe and engage with the dynamic process of osmosis. This hands-on method enhances learning, making complex physiological concepts accessible and practical. Ideal for resource-limited settings, it bridges theoretical knowledge and practical application, transforming physiology education.
PURPOSE: An anti-obesity composition including the extract and fractions of herbal medicine is provided to reduce effectively body weight and body fat without vivotoxin and suppress insulin tolerance, thereby using as medical supplies for prevention and treatment of obesity and health functional food. CONSTITUTION: Gyeongshingangjeehwan18 (GGEx18) is manufactured by mixing ephedrae Herba, laminariae japonicae thallus and rhei Rhizoma in a weight ratio of 10-50%:20-50%:20-50% based on weight of raw material. The GGEx18 is extracted with 50-80% of ethanol and condensed. Fractions are obtained by line separation in which the condensed GGEx18 is gradually separated with dichloromethane, ethyl acetate, butanol and water. The pharmaceutical composition for prevention and treatment of obesity includes the fraction as active ingredient. The fractions are dichloromethane fractions. The fractions are ehtylacetate fraction.
Once eligibility is confirmed, the patient will start treatment cycles with Pembrolizumab at 200 mg given intravenously on the first day of each cycle. Each cycle corresponds to a duration of 3 weeks.
Alkyd resins prepared by reacting an endoalkylene-tetrahydrophthalic acid with a polyhydric alcohol are used in conjunction with shellac and a liquid unsaturated high molecular weight fatty acid containing at least 10 carbon atoms, e.g. oleic, linoleic or linolenic acid for coating medicinal preparations for personal administration.  The examples illustrate the use of such resins prepared from 3-isopropyl-6-methyl-3 : 6 - endoethylene - D 4 - tetrahydrophthalic acid and glycol, 1 : 2 propanediol or glycerin and 3 : 6 - endo methylene - D 4 - tetrahydrophthalic acid and glycol.ALSO:A solid medicinal preparation for peroral administration comprises a medicament provided with a solid non-brittle lacquer coating containing an alkyl resin from an endo-alkylene-tetrahydrophthalic acid and a polyhydric alcohol, a liquid unsaturated fatty acid of high molecular weight containing at least 10 carbon atoms, and shellac.  The preferred alkyl resins are endomethylene or endoethylene tetrahydrophthalic acid glycol poly esters and the hydrophthalic acid residue may be substituted e.g. with alkyl residues.  The examples relate to the use of such resins prepared from 3 - isopropyl - 6 - methyl - 3 : 6 endoethylene - c 4 - tetrahydrophthalic acid and glycol, glycerin or 1 : 2 propandiol, and 3 : 6 endomethylene - c 4 - tetrahydrophthalic acid and glycol.  The fatty acid component of the lacquer is preferably oleic acid but linoleic or linolenic acids may be used.  The medicament may form the nucleus of the preparation or may be worked up by conventional methods to a granulate which is then coated with the lacquer or formed into units e.g. tablets which are then coated or be enclosed as a granular mix of coated and uncoated particles in a capsule soluble in the gastric juices.  Further medicament may be applied as an additional coating.  The medicaments used are active or absorbable in the intestine and the lacquer coating protects them from the action of the gastric juices.  Such medicaments may be phenyl-cyclohexyl-hydroxyacetic aciddiethylamino ethyl ester brommethylate, a-phenyl - a-ethylglutaric acid imide, 2 - (N - phenyl - N - benzylamino methyl) imidazoline hydrochloride and a - phenyl - a - piperidyl (2) acetic acid ethyl ester hydrochloride.
Physicians in the Calgary Health Region are using tinzaparin (predominantly) and other low molecular weight heparins (LMWHs) for the treatment venous thromboembolism (VTE) in pregnancy. The most recent anticoagulation guidelines from American College of Chest Physicians (ACCP) suggest that heparin levels (anti-Factor-Xa activity levels) may be done periodically through pregnancy to determine the need to adjust the dose of LMWH as pregnancy progresses. This monitoring is widely practiced. There is no clear consensus in the literature, however, with some experts suggesting that initial and subsequent dosing may be done based on weight alone (as is done in the non-pregnant population). Given the multiple physiologic changes which occur to drug metabolism during pregnancy, this bears further evaluation. To date, there is very limited data on weight-adjusted dosing of LMWH in pregnancy. This study is therefore designed to determine if dosing of tinzaparin during pregnancy based on weight, with periodic weight-based adjustments, will result in adequate therapeutic anticoagulation.
Participants began administration with 5 mg ruxolitinib twice daily (BID) orally. Beginning at the Week 4 visit, doses of ruxolitinib could be increased in 5 mg once a day (QD) increments every 4 weeks every 4 weeks not to exceed a dose of 25 mg BID.
The program is designed to serve individuals with severe and persistent mental illnesses who have been repeatedly hospitalized, are repeat users of community crisis services, or are frequently in contact with the criminal justice system. There are several objectives of this new approach. First, the investigators believe that these patients are invested in working with the daily dispensing program to stay well, but individual factors related to their personal background or symptoms of their illness contribute to frequent non-adherence to medications. Non-adherence to medications then leads to behaviour that results in frequent use of very expensive services such as the criminal justice system, acute care hospital beds, and crisis services. Working collaboratively with the patient to improve adherence to medications in partnership with a private pharmacy that absorbs costs of the program is a less coercive model than injectable medications, which is the current standard for working with this population. In addition, oral medications are much less expensive than the newer injectable antipsychotics and the costs of running a "depot clinic" where the injectable medications are provided. At this time, there has been no effective program to ensure compliance with oral medications in the published literature.

The primary purpose of this study is to evaluate the effectiveness of this new model for decreasing the harmful effects of relapses to psychosis resulting from non-adherence to medications. Specifically, the investigators plan to examine whether or not this program results in less use of crisis services, acute care hospitalization and less contact with the criminal justice system. The investigators plan to evaluate client response through a self-reported measure and to assess client satisfaction by conducting participant satisfaction survey for the program. Key stakeholders will be engaged during the process (e.g., community mental health workers, probation officers, pharmacists) to gather information and suggestions regarding the daily dispensing program. Based on feedback from clients and stakeholders, the investigators will then aim to implement improvements to the process to optimize its effectiveness.
The invention relates to an eucommia-clerodendrum bungei cigarette and a production method thereof. The invention is characterized in that the eucommia-clerodendrum bungei cigarette is produced with processed eucommia leaves coming from Cili county of Hunan province, shredded liquorice slices, clerodendrum bungei leaves and flue-cured tobacco leaves. The proportions of the eucommia leaves, the liquorice, the clerodendrum bungei leaves and the flue-cured tobacco leaves in total weight are as follows: 30 to 40 percent of eucommia leaves, 10 to 20 percent of liquorice, 30 to 40 percent of clerodendrum bungei leaves and 30 to 40 percent of flue-cured tobacco leaves. The eucommia leaves are processed for later use. A tool is used for cutting the fully sun-cured liquorice into 1mm to 2mm of shredded slices for later use. After being plucked in summer and autumn, the clerodendrum bungei leaves are washed by clean water, dried and sun-cured or baked for later use. The flue-cured tobacco leaves are purchased for later use. The eucommia-clerodendrum bungei cigarette can resist bacteria, viruses, tumors and cancers and treat cancers, all cigarette smokers can smoke the eucommia-clerodendrum bungei cigarette, and the eucommia-clerodendrum bungei cigarette not only can be smoked by people, but also can enhance the immunity of the body, and has a remarkable effect in preventing various diseases, so the eucommia-clerodendrum bungei cigarette is highly beneficial and can be accepted and liked by cigarette consumers.
By not only diagnosing colorectal cancer (CRC) at an early stage, but also removing precursor lesions (adenomas), colonoscopy with polypectomy reduces the risk of developing and dying from CRC. Approximately 90% of polyps are less than 10 mm and are easily removed by competent endoscopists. Laterally spreading lesions (LST) and sessile lesions of the colon, also known as advanced mucosal neoplasia (AMN) are underrecognised types of lesions that are more likely to progress to cancer. They include sessile serrated polyps (SSP), an emerging entity of flat polyps with malignant potential. Detection of hemoglobin (a component of blood) in stool is an established validated screening tool for CRC. Its specific role in the prediction of AMN, and particularly SSPs is yet to be defined. Blood tests measuring the level of tumour derived methylated deoxyribonucleic acid (DNA) in blood circulating have been demonstrated to have clinical utility for detection of CRC and AMN. A blood based CRC screening test has the potential to increase compliance. This study aims to determine the clinical utility of stool and blood methylation tests for detection of AMN and SSPs. Stool and blood will be obtained from consenting patients referred for endoscopic removal of known ANM and SSP (study arm) as well as from consenting patients scheduled for colonoscopy screening (control arm). The level of stool hemoglobin and methylated tumour derived DNA in circulation will be measured in the two study groups. Cutoff values will be generated to assess best predictive capability of high risk lesions based on these tests.
PURPOSE:A high-safety anticonvulsant that contains, as an active ingredient, coenzyme Q, thus being effective on central contraction, especially used as a preventive or remedy for epilepsy with high efficacy. CONSTITUTION:Anticonvulsant is obtained by using coenzyme Q of the formula (n is integer of 7-10). Coenzyme Q has been thought to be a coenzyme participating the electron transport system in the mitocondrian in a living body to play an important role by activating cytorespiration, increasing the production of ATP and activating individual tissues in a living body. Coenzyme Q10(n is 10) has been known as a remedy for congestive failure, however, it has been found that it is effective as a preventive or remedy for convulsions. Coenzyme Q, especially coenzyme Q10 is effective on prevention and treatment for convulsions. It has high safety and can be administered for a long period of time. The dose is preferably 20-500mg/day/adult.
A trans-epithelial PTK procedure will be performed using the MEL 90 excimer laser. The refractive outcome will be compared to the refractive change predicted by the EpiMaster application software.
The metabolism of (poly)phenols and some host metabolites, including bile acids (BAs) and cholesterol, varies among individuals depending on their gut microbiota. The gut microbial metabolism of ellagitannins (ETs) and ellagic acid (EA) produces urolithins (Uros), yielding three metabotypes with quantitative and qualitative differences based on dissimilar Uro-producing profiles (UM-A, UM-B, and UM-0, i.e., non-producers). Previous animal studies demonstrated that polyphenols impact BAs and cholesterol microbial metabolism, but data on their effects in humans and data regarding the inter-individual variability of these metabolic conversions are scant. We evaluated whether UMs, as distinctive functional gut-microbiome signatures, could determine the potential effect of a pomegranate extract (PE) rich in ET-EA on the metabolism of BAs and cholesterol in mild dyslipidaemic overweight-obese individuals, with possible consequences on host-lipid homeostasis and gut health. At the baseline, UM-B presented the highest levels of faecal total and secondary BAs and coprostanol, suggesting that the lipid absorption capacity and gut cytotoxic risk could be augmented in UM-B. PE intake significantly reduced faecal coprostanol and BA production, especially secondary BAs, and modulated the gut microbiome, reducing the gut cytotoxic risk, especially in UM-B individuals. The lowering of faecal microbial coprostanol and BAs and some BA-metabolising bacteria was quantitatively correlated with Uro concentrations, mainly faecal Uro-A. This suggests that PE consumption could exert cardiovascular and gut protection through Uro-A production as a direct driver of the effects and indirectly by reducing the Coriobacteriaceae family and BA pool, known factors involved in the gut absorption of lipids.
Apremilast (60mg/day). Administered orally twice daily at 8:00 AM and 8:00 PM while titrating to the full dose. Titration schedule: Day 1 10mg AM; Day 2 10mg AM, 10mg PM; Day 3 10mg AM, 20mg PM; Day 4 20mg AM, 20mg PM; Day 5 20mg AM, 30mg PM; Day 6 30mg AM, 30mg PM. Once at steady state, administration is orally twice daily at 8:00 AM (30mg) and 8:00 PM (30mg).
Sulforaphane (SF) is an isothiocyanate found in high levels in crucifers belonging to the family Brassicaceae (including broccoli, cabbage, cauliflower, brussels sprouts, Chinese cabbage and turnips). Many previous studies have documented that consumption of these vegetables is associated with a reduced risk of cancer (lung, breast, colon, rectum, and prostate).(Juge et al. 2007) The mechanism of action of these beneficial effects is believed to be due to the ability of SF to up-regulate genes that improve cellular response to oxidative stress, inflammation, DNA-damaging electrophiles, and radiation.(Singh et al. 2014) In a recent small, randomized controlled trial in children with autism, SF was shown to have beneficial effects on aberrant and social behavior.(Singh et al. 2014) The mechanism of action of this beneficial effect has not been established in children with ASD. Our primary goal is to examine changes in urinary metabolites in children with autism who receive SF to determine if changes in behavior are associated with changes in urinary metabolites.
The invention provides an external traditional Chinese medicine composition for treating cough variant asthma of an adult. The external traditional Chinese medicine composition uses perillaseed and cynanchum glaucescens as a monarch medicine, uses radish seed, flos farfarae, fritillaria and the root bark of white mulberry as a ministerial medicine, uses agilawood as an adjuvant medicine and uses liquorice as a conductant medicine. The external traditional Chinese medicine composition has a reasonable receipt, and uses a traditional acupoint therapy and a transdermal absorption principle in modern pharmacy. The traditional Chinese medicine composition provided by the invention is respectively adhered to a Tiantu acupoint, Feishu acupoints at the both sides, a Dingchuan acupoint, a Fenglong acupoint and a Shenshu acupoint of a human body, so as to treat the cough variant asthma of the adult. Particularly, according to the specific therapy of winter disease cured in summer in a traditional Chinese medicine, the acupoints are adhered in dog days. A dosing method is simple and convenient; the medicinal effect is reliable and lasting; and no untoward effect exists. The external traditional Chinese medicine composition has the functions of conducting through channels and collaterals, tonifying yang, dispersing in-vivo severe pathogenic cold, reducing phlegm in a temper manner, inspiring healthy atmosphere of the human body, supporting the healthy energy, and preventing and treating the diseases. The treatment cost is low. The total efficiency is 88.7%. The external traditional Chinese medicine composition provided by the invention is an effective medicine for treating the cough variant asthma of the adult.
A cosmetic composition, typically, including about 0.01 to about 3 wt. % of retinol; about 0.5 to about 10 wt. % of sodium polyacrylate; about 0.25 to about 10 wt. % of one or more nonionic emulsifier; about 3.5 to about 12 wt. % of a fatty phase, wherein the fatty phase comprises one or more fatty compound; and water, wherein all weight percentages are based on the total weight of the cosmetic composition. The cosmetic composition may be an oil-in-water emulsion.
Gemcitabine and Abraxane will be administered on an outpatient basis on Days 3, 10, 17, 31, 38, and 45 as an intravenous infusion. The dose on Day 3 will be 1000 mg/m of gemcitabine followed by a 125 mg/m2 of abraxane and the infusion will take 1 hour. The second dose and infusion time may be decreased. Prior to each gemcitabine infusion, subjects will be pre-medicated with an FDA-approved anti-emetic (anti-nausea medication) in an effort to prevent nausea, at the discretion of the study physician.